News tagged ‘ChildhoodCancer’ clear
- New findings led by researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center show informing parents about their child's cancer prognosis – even when the prognosis is less than favorable – is much more likely to give parents peace of mind and hope rather than increase their anxiety or cause them to become depressed.
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center has joined a Memorial Sloan Kettering clinical trial of immunotherapy for children with relapsed or treatment-resistant acute lymphoblastic leukemia. Dana-Farber/Boston Children’s is the only site in New England to offer this breakthrough experimental approach that triggers a patient's immune system to attack cancer cells.
Tags: ChildhoodCancer, Immunotherapy
- Scientists at Dana-Farber/Boston Children's Cancer and Blood Disorders Center have identified a protein critical to both normal brain development and, in many cases, the development of medulloblastoma, a fast-growing brain tumor that usually strikes children under 10. According to a report in the journal Developmental Cell, halving the level of the protein Eya1 in mice prone to develop medulloblastoma dramatically reduced the animals' risk of dying from the disease.
Tags: ChildhoodCancer, BrainTumors
- Common variations in four genes related to brain inflammation or cells' response to damage from oxidation may contribute to the problems with memory, learning and other cognitive functions seen in children treated for acute lymphoblastic leukemia (ALL), according to research presented at the annual American Society of Hematology annual meeting in San Francisco.
Tags: ChildhoodCancer, Survivorship, Leukemia
- Researchers have found a way to defeat one of the most tantalizing yet elusive target proteins in cancer cells by turning the protein's own molecular machinations against it. In a study published online by the journal Cell, the scientists used a specially crafted compound to disrupt the protein's ability to rev up its own production and that of other proteins involved in tumor cell growth.
Tags: ChildhoodCancer, TargetedTherapy, TranscriptionFactors
- David G. Nathan, MD, president emeritus of Dana-Farber Cancer Institute and physician-in-chief emeritus of Boston Children's Hospital, was honored as the inaugural recipient of the Boston Children’s Hospital Lifetime Impact Award at the hospital’s second Annual Global Pediatric Innovation Summit, Taking on Tomorrow (#PedInno14).
Tags: ChildhoodCancer, Honors
- Boston Mayor Martin Walsh reflected on his successful fight against childhood lymphoma at Dana-Farber’s annual celebration of survivorship. He was diagnosed at age 7 with Burkitt’s lymphoma, a rare, aggressive form of non-Hodgkin lymphoma that primarily affects children.
Tags: ChildhoodCancer, Survivorship
- One of the first studies to analyze the effectiveness of screening survivors of childhood cancer for early signs of impending congestive heart failure (CHF) finds improved health outcomes but suggests that less frequent screening than currently recommended may yield similar clinical benefit.
Tags: ChildhoodCancer, Survivorship
- Researchers studying a rare, always fatal brain tumor in children have found several molecular alterations that drive the cancer, according to a new study from scientists at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and McGill University. The findings, published in Nature Genetics, identify potential new targets for drug treatments.
Tags: ChildhoodCancer, Genomics, TargetedTherapy, BrainTumors
- A normal enzyme called SYK pairs with FLT3, the most commonly mutated enzyme found in acute myelogenous leukemia, to promote progression of the cancer and its resistance to treatment with FLT3-blocking drugs, which may explain relatively poor results in clinical studies. In a mouse model, treatment with a combination of drugs to inhibit the two enzymes was more effective than treatment with either drug alone.
Tags: chemotherapy, BasicResearch, ChildhoodCancer, Leukemia